WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to "cut a deal" with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today)

Building a better obesity drug is no easy task. Obesity involves a host of genetic, behavioral, emotional and socio-cultural factors. And any successful drug will be taken by millions of patients, resulting in a safety hurdle that will "probably be greater than for any other drug out there," Kasimov said. (BioWorld Financial Watch)